| Name | Title | Contact Details |
|---|
Villa Stanley is a Los Angeles, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
First Dental Health is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Central Pennsylvania Blood Bank is a Hummelstown, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Since day one, we`ve been dedicated to delivering personalized, innovative, and impactful workplace wellness programs. Provant is a health and wellness solutions company that partners with businesses to build cultures of health designed to improve the health, well-being, and productivity of employees while supporting employers with their healthcare affordability agenda. Provant`s Life+ Program combines personalized “high touch” services with powerful social networking tools that link rewards to healthy behaviors and outcomes. The results of these programs: exceptional engagement, improved health, productive employees, and lower costs. Founded in 2001, Provant serves customers of all sizes across the United States, Puerto Rico, Canada, and the Caribbean. Our customizable program is delivered to millions of people and consist of assessment services (e.g. screening services, flu vaccinations), inspirational services (e.g. coaching, lifestyle and condition programs) and reward and reporting services (participation-based and outcome-based programs). Program innovation, customization, and a comprehensive, quality approach to managing health risks are at the cornerstone of everything that we do. Our leadership team consists of seasoned wellness and business professionals with extensive experience in the health promotion, wellness, consumerism, medical, insurance, and hospital arenas. Our commitment to what we do is based on a sincere desire to promote wellness, to partner with our clients, and to work as a team. Improving lives in the process is what makes it all worthwhile.
Discovery Laboratories, Inc. is a specialty biotechnology company focused on advancing a new standard in respiratory critical care. Discovery Labs` technology platform includes its novel proprietary KL4 surfactant, a synthetic, peptide-containing surfactant that is structurally similar to pulmonary surfactant, and its proprietary drug delivery technologies being developed to enable efficient delivery of aerosolized KL4 surfactant and other inhaled therapies. Discovery Labs` strategy is initially focused on neonatology and improving the management of respiratory distress syndrome (RDS) in premature infants. Discovery Labs believes that its RDS product portfolio has the potential to become the new standard of care for RDS and, over time, enable the treatment of a significantly greater number of premature infants who could benefit from surfactant therapy that are currently not being treated. In many pulmonary diseases, including RDS, acute lung injury (ALI), and other respiratory conditions, surfactant is either deficient or may fail to function properly. Our precision-engineered, peptide-containing KL4 surfactant has been designed to mimic the essential function of human pulmonary surfactant and may have the potential to address conditions such as these. We are developing our proprietary delivery technologies to one day enable efficient, targeted upper-respiratory or alveolar delivery of our KL4 surfactant in aerosolized form to allow for a gentler, less invasive delivery approach. These same delivery systems may also potentially be used to deliver a variety of additional aerosolized medicines safely and in a simplified way compared with the current standard of care.